# SPRY catalysts: ARS Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/spry/catalysts

> ARS Pharmaceuticals, Inc. (SPRY) has 3 upcoming catalysts. The next is the ARS Pharmaceuticals, Inc. interim data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for SPRY?

ARS Pharmaceuticals, Inc. (SPRY) has 3 upcoming catalysts. The next is the ARS Pharmaceuticals, Inc. interim data readout, Q1 2027. Press release filed with the SEC (EX-99): "Interim data from the Phase 2b trial are expected in the first quarter of 2027, with full data later in 2027, which will inform the design of a potential Phase 3 registration program." [Calendar and source filings](https://sec-api.dev/companies/spry/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-449748, https://www.sec.gov/Archives/edgar/data/1671858/000119312526449748/spry-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/spry/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | ARS Pharmaceuticals, Inc. |
| Ticker | SPRY (Nasdaq) |
| SEC CIK | 1671858 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/spry |

## Cash runway

Cash $138.4M as of 2026-09-30; quarterly burn $33.7M; about 12.3 months of runway at that rate (XBRL company facts, accession 0001193125-26-449778).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 19, 2023 | [ARS Pharmaceuticals, Inc. complete response letter (CRL)](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed, complete response letter | "On September 19, 2023, the FDA issued a complete response letter ("CRL") for our NDA requesting completion of a PK/PD study assessing repeat doses of neffy compared to repeat doses of an epinephrine injection product under allergen-induced allergic rhinitis." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1671858/000095017025042320/spry-20241231.htm)) |
| September 19, 2023 | [Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate) complete response letter (CRL)](https://sec-api.dev/pdufa/epinephrine) | SPRY |  | completed, complete response letter | "We have completed our review of this NDA, as amended, and have determined that we cannot approve this NDA in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22214697_2025_Orig1s000OtherActionLtrs.pdf%22)) |
| Feb 2024 | [Allergies topline data readout](https://sec-api.dev/pdufa/allergies) | SPRY |  | completed, met | "We reported positive topline results demonstrating statistically significant and clinically meaningful improvements in treatment-refractory chronic urticaria patients at the American Academy of Allergy and Immunology medical conference in February 2024, and anticipate initiating a Phase 2b randomized placebo-controlled outpatient clinical trial in chronic spontaneous urticaria patients who are on a chronic antihistamine regimen, but still experience flares, in the second quarter of 2025, with topline data anticipated in early 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1671858/000095017025042320/spry-20241231.htm)) |
| August 9, 2024 | [ARS Pharmaceuticals, Inc. FDA approval](https://sec-api.dev/companies/spry/catalysts) | SPRY | Type 1 allergic reactions | completed, approved | "On August 9, 2024, the FDA approved neffy® (epinephrine nasal spray) 2 mg for the treatment of Type 1 allergic reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). neffy was first available for shipment on September 23, 2024, and in early October, the U.S. sales force started in the field and neffy became broadly available in retail pharmacies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017024125921/spry-ex99_1.htm)) |
| Sep 2024 | [ARS Pharmaceuticals, Inc. NDA/BLA submission](https://sec-api.dev/companies/spry/catalysts) | SPRY | Type I allergic reactions | completed | "In September 2024, ARS Pharma submitted a supplemental New Drug Application (sNDA) for neffy 1 mg for the treatment of Type I allergic reactions, including anaphylaxis, in adults and children who weigh 15 to 30 kg (33-66 lbs.)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017024125921/spry-ex99_1.htm)) |
| September 30, 2024 | [ARS Pharmaceuticals, Inc. FDA approval](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed, approved | "Our remaining payment obligations to Aegis that are contingent upon our achievement of certain regulatory and commercial milestones have been reduced to $16.0 million as of September 30, 2024 due to the $2.5 million milestone payment that was made in August 2024 for achieving FDA approval of neffy." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1671858/000095017024125924/spry-20240930.htm)) |
| November 13, 2024 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017024125921/spry-ex99_1.htm)) |
| March 5, 2025 | [ARS Pharmaceuticals, Inc. label expansion decision](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed, approved | "U.S. Pediatric Approval: On March 5, 2025, the U.S. FDA approved ARS Pharma's sNDA for neffy 1 mg as an emergency treatment for Type I allergic reactions, including anaphylaxis, in children aged four and older and weighing 15 kilograms to < 30 kilograms (33 to <66 lb.). neffy 1 mg is expected to be available in pharmacies starting in May 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017025042317/spry-ex99_1.htm)) |
| March 5, 2025 | [ARS Pharmaceuticals, Inc. FDA approval](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed, approved | "On March 5, 2025, ARS Pharmaceuticals, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") approved neffy 1 mg (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including anaphylaxis, in children who are aged four years and older and weigh ≥15 kilograms to <30 kilograms (≥33lbs. to <66 lbs.)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1671858/000119312525047351/d831088d8k.htm)) |
| March 6, 2025 | [ARS Pharmaceuticals, Inc. PDUFA date](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | scheduled | "Drug User Fee Act (PDUFA) target action date of March 6, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312525005014/d910559dex991.htm)) |
| March 20, 2025 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017025042317/spry-ex99_1.htm)) |
| May 14, 2025 | [ARS Pharmaceuticals, Inc. FDA approval](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed, approved | "SAN DIEGO, May 14, 2025 - ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced financial results for the first quarter of 2025 and provided an update on the continued U.S. commercial launch of neffy® (epinephrine nasal spray), the first and only FDA approved and European Commission approved needle-free epinephrine treatment for Type I allergic reactions, including anaphylaxis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017025070899/spry-ex99_1.htm)) |
| May 14, 2025 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017025070899/spry-ex99_1.htm)) |
| August 13, 2025 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017025107617/spry-ex99_1.htm)) |
| November 10, 2025 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312525273107/spry-ex99_1.htm)) |
| 1H 2026 | [ARS Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | scheduled | "The trial is enrolling patients in the U.S. and Europe, with topline data anticipated in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017025107617/spry-ex99_1.htm)) |
| Mar 2026 | [ARS Pharmaceuticals, Inc. FDA approval](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed, approved | "Removal of age criteria from 1 mg neffy: FDA approved removing the age criteria in late March 2026, so all children and adults who weigh 33 lbs or more can utilize neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/spry-ex99_1.htm)) |
| March 9, 2026 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization neffy delivers $72.2 million of U.S. net product revenue in first full year" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097467/spry-ex99_1.htm)) |
| mid-2026 | [ARS Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/spry/catalysts) | SPRY | chronic spontaneous urticaria, with topline data | scheduled | "Phase 2b trial in urticaria ongoing: A Phase 2b trial (NCT06927999) to evaluate intranasal epinephrine technology as a treatment for acute flares is enrolling patients with chronic spontaneous urticaria in the U.S. and Europe, with topline data anticipated in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312525273107/spry-ex99_1.htm)) |
| mid-2026 | [ARS Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | scheduled | "Topline data from this clinical trial is anticipated in mid-2026, followed by the potential initiation of a single pivotal efficacy study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1671858/000119312525273111/spry-20250930.htm)) |
| May 15, 2026 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/spry-ex99_1.htm)) |
| 2H 2026 | [ARS Pharmaceuticals, Inc. interim data readout](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | scheduled | "Phase 2b trial in urticaria ongoing: A Phase 2b trial (NCT06927999) evaluating the company's intranasal epinephrine technology as a treatment for acute flares of chronic spontaneous urticaria is enrolling patients across the U.S. and Europe, with interim data anticipated in the second half of 2026 followed by the potential initiation of a single pivotal efficacy study in mid-2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097467/spry-ex99_1.htm)) |
| August 13, 2026 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526349127/spry-ex99_1.htm)) |
| Q4 2026 | [ARS Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | scheduled | "Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/spry-ex99_1.htm)) |
| November 5, 2026 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526449748/spry-ex99_1.htm)) |
| Q1 2027 | [ARS Pharmaceuticals, Inc. interim data readout](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | scheduled | "Interim data from the Phase 2b trial are expected in the first quarter of 2027, with full data later in 2027, which will inform the design of a potential Phase 3 registration program." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526449748/spry-ex99_1.htm)) |
| June 2027 | [ARS Pharmaceuticals, Inc. primary completion](https://sec-api.dev/companies/spry/catalysts) | SPRY | Urticaria Chronic | scheduled | "NCT06927999 (An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor ARS Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06927999)) |
| Jun to Sep 2027 | [ARS Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/spry/catalysts) | SPRY | Urticaria Chronic | scheduled | "NCT06927999 (An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor ARS Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06927999)) |

## Drugs

- [Allergies](https://sec-api.dev/pdufa/allergies): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/spry/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SPRY catalysts: ARS Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/spry/catalysts

```bibtex
@misc{secapidev_companies_spry_catalysts_20261116,
  title        = {SPRY catalysts: ARS Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/spry/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_spry_catalysts_20261116","title":"SPRY catalysts: ARS Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/spry/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
